8 active not recruiting, 6 recruiting, 4 completed, 2 terminated. 11 Phase 1, 7 Phase 2, 3 Not applicable, 1 Phase 3.
Follow Unresectable Lung Non-Small Cell Carcinoma: new trials by email Literature Review of Unresectable Lung Non-Small Cell Carcinoma trials Research Report on Unresectable Lung Non-Small Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Recruiting | University of Rochester | 800 | 2023-12-04 | 2026-01-09 | |
| A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC serplulimab plus chemotherapy as conversion treatment - Unresectable Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | Zhejiang University | 49 | 2023-05-15 | 2023-07-17 |
| Understanding New Cachexia Subtypes Through Observational Epidemiological Research Biospecimen Collection, Computed Tomography, Electronic health record review - Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Recruiting | Kaiser Permanente | 800 | 2023-04-05 | 2026-08-20 | |
| Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 28 | 2022-06-09 | 2026-07-22 |
| Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial Best Practice, Exercise Intervention, Physical Therapy - Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma | Not applicable | Completed | Ohio State University Comprehensive Cancer Center | 100 | 2022-04-14 | 2025-11-21 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer Biopsy, Osimertinib, Triptolide Analog - Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 8 | 2022-03-07 | 2026-03-05 |
| Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer Carboplatin, Durvalumab, Paclitaxel - Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 28 | 2021-12-06 | 2026-06-30 |
| Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer Computed Tomography, Contrast Agent - Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Not applicable | Active not recruiting | Rutgers, The State University of New Jersey | 34 | 2021-02-11 | 2026-06-11 |
| NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer Hafnium Oxide-containing Nanoparticles NBTXR3, Radiation Therapy - Recurrent Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8 | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 34 | 2021-02-10 | 2026-08-19 |
| Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Carboplatin, Cisplatin, Durvalumab - Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 660 | 2020-04-29 | 2026-10-22 |
| Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy Carboplatin, Paclitaxel, Pevonedistat - Metastatic Lung Non-Small Cell Squamous Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 27 | 2020-04-16 | 2026-09-22 |
| Resiliency Among Older Adults Receiving Lung Cancer Treatment Physical Therapy, Quality-of-Life Assessment, Questionnaire Administration - Advanced Lung Carcinoma, Extensive Stage Lung Small Cell Carcinoma | Not applicable | Completed | Ohio State University Comprehensive Cancer Center | 18 | 2020-01-22 | 2023-11-15 |
| Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial Accelerated Hypofractionated Radiation Therapy, Biospecimen Collection, Computed Tomography - Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2019-10-28 | 2025-09-23 |
| Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer Ipilimumab, Nivolumab, Radiation Therapy - ALK Gene Rearrangement, EGFR Gene Mutation | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 21 | 2019-09-13 | 2026-09-14 |
| Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced Pembrolizumab, Pharmacokinetic Study, Trametinib - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 37 | 2018-02-03 | 2026-07-16 |
| Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Carboplatin, Cisplatin, Etoposide - Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 2 | Completed | Mayo Clinic | 20 | 2017-07-31 | 2025-11-25 |
| CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab - Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 51 | 2016-12-22 | 2026-08-10 |
| Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies Laboratory Biomarker Analysis, ROR1 CAR-specific Autologous T-Lymphocytes - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 21 | 2016-03-16 | 2022-08-31 |
Showing 20 of 21. Sign in to see all of them.
Lung Neoplasms (19) · Carcinoma, Non-Small-Cell Lung (12) · Melanoma (4) · Neoplasm Metastasis (4) · Carcinoma, Renal Cell (3) · Colorectal Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Triple Negative Breast Neoplasms (3) · Carcinoma, Merkel Cell (2) · Carcinoma, Transitional Cell (2) · Pancreatic Neoplasms (2) · Uterine Cervical Neoplasms (2) · Carcinoma, Basal Cell (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Lobular (1)
Lung Diseases (19) · Neoplasms (19) · Neoplasms by Site (19) · Respiratory Tract Diseases (19) · Respiratory Tract Neoplasms (19) · Thoracic Neoplasms (19) · Bronchial Neoplasms (12) · Carcinoma, Bronchogenic (12) · Neoplasms by Histologic Type (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Carcinoma (4) · Neoplasms, Germ Cell and Embryonal (4)
Magnetic Resonance Spectroscopy (6) · Specimen Handling (6) · Carboplatin (5) · Nivolumab (5) · Paclitaxel (5) · Taxes (5) · Immunoglobulin G (4) · Pemetrexed (4) · Radiation (4) · Radiotherapy (4) · pembrolizumab (4) · Biopsy (3) · Contrast Media (3) · Disulfides (3) · durvalumab (3)
M.D. Anderson Cancer Center (4) · Fred Hutchinson Cancer Center (3) · National Cancer Institute (NCI) (3) · Ohio State University Comprehensive Cancer Center (3) · Mayo Clinic (2) · City of Hope Medical Center (1) · Kaiser Permanente (1) · Roswell Park Cancer Institute (1) · Rutgers, The State University of New Jersey (1) · University of Rochester (1) · Zhejiang University (1)
United States (19) · China (1) · Guam (1) · Uganda (1)
Anne S Tsao (1) · Aung Naing, MD (1) · Carolyn J Presley, MD (1) · Carolyn J Presley, MD, MHS (1) · David Maloney (1) · Erminia Massarelli (1) · Ferdinandos Skoulidis, MD,PHD (1) · Jeremey Brownstein, MD (1) · Joshua Veatch (1) · Nathan A Pennell (1) · Prantesh Jain, MD (1) · Richard F Dunne (1) · Salma K Jabbour, MD (1) · Saumil Gandhi (1) · Shailender Bhatia, MD (1)
PMID 33357452, PMID 33909232, PMID 34562230, PMID 34965890, PMID 36873868, PMID 37129197, PMID 39816915, PMID 39945382
K76AG074923 (1), OT2CA278691 (1), P30CA016672 (1), P30CA033572 (1), P30CA072720 (1), R01CA114536 (1), R01CA155196 (1), R01CA262388 (1), R03AG064374 (1), U10CA180820 (1), U10CA180868 (1), UG1CA189961 (1), UM1CA186691 (1), UM1CA186716 (1)